The ATM filing adds persistent overhang on IFRX shares. While the company has a long cash runway, the market may price in continued dilution. Monitor the pace of actual share sales via quarterly disclosures; any acceleration in selling could pressure the stock further. The stock has a history of volatile reactions to filings, but the pattern of repeated ATM offerings is a structural headwind.
Price Chart
Executive Summary
InflaRx N.V. filed a 424B5 prospectus supplement to register up to $65 million in ordinary shares for an at-the-market offering through Leerink Partners. This is a continuation of the company's existing ATM program, with the proceeds intended to fund R&D and general corporate purposes. The filing represents a dilutive capital raise for a pre-revenue biotech with a $296M market cap, but the company estimates its existing cash runway extends into 2029, partially mitigating urgency concerns.
Key Facts
- Up to $65,000,000 in ordinary shares registered for at-the-market offering through Leerink Partners.
- Commission rate of up to 3.0% of gross proceeds.
- As of June 30, 2026, the company had €158.4 million in cash, cash equivalents, and marketable securities.
- Net tangible book value as of June 30, 2026 was $165.6 million ($1.12 per share); after full offering, estimated at $228.5 million ($1.27 per share), implying $0.74 dilution per share at $2.01 assumed price.
- 147,368,221 ordinary shares outstanding as of June 30, 2026; up to 32,338,308 additional shares could be issued at $2.01.
- Company estimates existing funds sufficient to fund operations into end of 2029.
- This is the 5th offering/registration filing in the last 24 months, indicating a pattern of equity dilution.
Financial Impact
Up to $65 million in gross proceeds; approximately $0.74 per share dilution to new investors at assumed $2.01 price; 3% commission to Leerink Partners.
Risk Factors
- Dilution from ongoing ATM sales could pressure share price.
- Company is pre-revenue with no approved products generating meaningful sales; GOHIBIC EUA being terminated.
- PFIC status likely, creating adverse tax consequences for U.S. holders.
- Baby Shelf Limitation risk if public float falls below $75 million, constraining future capital raises.
- Reliance on clinical-stage pipeline (izicopan, vilobelimab) with no guarantee of regulatory success.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 424B5 Filing (Primary) | 0001140361-26-033149 |
| Document: 0001140361-26-033149-index-headers.html | 0001140361-26-033149 |
| Document: 0001140361-26-033149-index.html | 0001140361-26-033149 |
| Document: 0001140361-26-033149.txt | 0001140361-26-033149 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 22, 2026 4d ago | 6-K | $1.56 | awaiting T+20 | — | $1.63 (+4.81%) |
Oct 22, 2026 5d ago | Press Release | $1.53 | awaiting T+20 | — | $1.63 (+6.86%) |
Oct 2, 2026 25d ago | Press Release | $1.72 | awaiting T+20 | — | $1.63 (−4.94%) |
Oct 1, 2026 26d ago | Press Release | $1.71 | awaiting T+20 | — | $1.63 (−4.39%) |
Aug 14, 2026 10w ago | 424B5 | $2.07 $2.02 | ▲ +2.42% | ▲ +0.44% | $1.63 (+21.01%) |
Aug 13, 2026 10w ago | EFFECT | $2.01 $2.09 | ▼ −3.98% | ▼ −5.73% | $1.63 (+18.66%) |
Aug 6, 2026 11w ago | 6-K | $1.72 $2.23 | ▲ +29.65% | ▲ +29.05% | $1.63 (−4.94%) |
Jun 30, 2026 16w ago | 6-K | $2.33 $1.65 | ▼ −29.18% | ▼ −27.00% | $1.63 (−29.83%) |
Jun 30, 2026 17w ago | Press Release | $2.24 $1.70 | ▼ −24.11% | ▼ −23.08% | $1.63 (−27.01%) |
May 6, 2026 24w ago | 424B5 | $2.65 $2.06 | ▲ +22.26% | ▲ +25.40% | $1.63 (+38.30%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers